Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions comprising Ibuprofen using solventless mixing methods. Excess coating material that is not bound to coated Ibuprofen may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Additionally, the compositions can be formulated to preserve the functional coating of coated Ibuprofen and to minimize aeration of Ibuprofen when mixed into suspension.

Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions using solventless mixing methods. Excess coating material that is not bound to a coated API particle may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Specifically, a coating ratio and/or a dosing ratio can be used to minimize the residual amount of excess unbound coating material to minimize agglomeration of coating material during storage. In some embodiments, a pharmaceutical composition is provided, the pharmaceutical composition comprising: 65-85% w/w API particles; 15-30% w/w coating material coating the API particles; and 3-15% w/w matrix surrounding the coated API particles, wherein the pharmaceutical composition comprises a disintegration time rate of less than 10 seconds for at least six months under storage conditions of at least 25° C. and at least 60% relative humidity.

The present invention relates to a method for subjecting a subject to an augmented reality (AR) or virtual reality (VR) experience. The method may comprise administering to the subject a composition comprising a cannabinoid compound. The method may comprise, subsequent to the administration of the composition comprising the cannabinoid compound, using an AR or VR device to subject the subject to an AR or VR experience. The method may comprise detecting a response of the subject to the AR or VR experience and the composition comprising the cannabinoid compound.

A method of preparing water-soluble lutein ester microcapsules includes: mixing marigold flower particles with an extracting solvent, refluxing at 65-85° C.; removing the extracting solvent to obtain a crude extract; washing the crude extract with a washing solvent; removing the washing solvent to obtain a crude lutein ester; adding an oil-phase antioxidant and a vegetable oil to the crude lutein ester, mixing and heating at 90-100° C. to obtain a lutein ester oil phase; adding a wall material, an emulsifier, a water-phase antioxidant, and a water-phase filler into water, and heating to obtain a water phase; adding the lutein ester oil phase to the water phase under a high-speed shearing, mixing evenly, and homogenizing to obtain a lutein ester emulsion; drying twice to obtain semi-finished lutein ester microcapsules; and solidifying to obtain the lutein ester microcapsules. Water-soluble lutein ester microcapsules prepared by the method are also disclosed.

This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.

Film-forming compositions for soft capsule formation have from 2 to 20 percent by weight of a mixture of hydroxyalkylated plant starch and a plant sugar, from 15 to 25 percent by weight agar, no more than 5 percent by weight gelatin, no more than 1 percent by weight carrageenan, and water as the balance thereof. Soft capsules made from such a film-forming composition and methods of making the same are also disclosed.

Disclosed herein are methods for preparing sporopollenin exine capsules (SECs) and methods for preparing composite materials that comprise SECs that utilize ionic liquid compositions. The composite materials typically include structural polymers and the SECs, and the SECs optionally may encapsulate useful materials, such as flame retardant materials, phase change materials, and therapeutic materials, such as probiotics and prebiotics. The composite materials may be prepared from ionic liquid compositions comprising the structural polymers and the SECs which optionally may encapsulate the useful materials, where the ionic liquid is removed from the ionic liquid compositions to obtain the composite materials comprising the SECs. The composite materials may be used in applications include (1) wound dressings to cool down damaged tissue; (2) as textiles to regulate the body temperature; (3) in building materials to regulate building temperature; (3) to provide fire retardation in textile and building materials; and (4) to deliver and protect probiotics and prebiotics from acidic conditions and digestive enzymes in the stomach, so that they fully retain their biological activity in the guts.

The present invention relates to a cancer cell-targeted drug delivery carrier, a composition for promoting photo-thermal treatment effects, and the like, which contain M1 macrophages as an active ingredient. The drug delivery carrier of the present invention uses the M1 macrophages mobility to tumor cells and the M1 macrophage penetrability into tumors, and can deliver drugs specifically to tumor and cancer tissues only, and, when performing photo-thermal treatment by loading M1 macrophages with a photosensitive material, can significantly increase the effects, and thus is expected to be effectively used for promoting cancer treatment effects.

Compositions are disclosed herein that include an extracellular matrix (ECM) hydrogel and matrix bound nanovesicles (MBV). These compositions provide a synergistic effect and are of use for treating subjects.

Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions that preserve the coating of coated API particles in a pharmaceutical suspension. Pharmaceutical compositions include coated active pharmaceutical ingredient (API) particles comprising: an API particle; a first coating comprising one or more deformed components coating the API particle; a second coating comprising silica surrounding and/or partially or fully embedded into the first coating, a matrix former, and a structure former.